1196Array ( )

Contexte et défis

Historiquement très rentable, le secteur vit une mutation accélérée dans un contexte de pression économique forte, d’exigences réglementaires croissantes, de compétivité prix et services sur les produits OTC (Over The Counter), de dérégulation et de rationalisation des dispositifs de santé publique.

Pour relever ces nombreux défis, les laboratoires pharmaceutiques doivent améliorer sans relâche le service qu’ils proposent à leurs clients. Cela suppose de mettre sur le marché de nouveaux médicaments et de développer des services aux patients et aux prescripteurs, et ce, en tirant parti des opportunités offertes par le digital.

Les laboratoires doivent plus que jamais amortir les coûts croissants de R&D en cherchant des effets d’échelle à travers des synergies industrielles ou de distribution. Ceci se traduit par une nécessaire maîtrise des intégrations post-acquisition sur les dimensions organisation, processus et SI.

Non seulement les entreprises doivent être plus flexibles mais elles doivent : 

  • maîtriser leurs coûts ;
  • adapter leur stratégie de distribution ;
  • améliorer le pilotage de la demande et du modèle de collaboration entre acteurs à travers la maîtrise de l’équilibre entre demande, stocks et capacité industrielle ;
  • faire évoluer leur modèle industriel (points de découplage, différenciation retardée, taille de campagne…) ;
  • optimiser leur politique de stocks ;
  • réduire les cycles de production ;
  • gérer les change controls.

Notre approche

Nous accompagnons nos clients du secteur dans leur transformation, depuis l’évaluation des enjeux jusqu’à la mise en œuvre des leviers d’amélioration de la performance sur l’ensemble de la chaîne des opérations : 

  • stratégie des opérations : gouvernance et organisation de la supply chain et des opérations, make or buy et footprint industriel, réduction de la complexité catalogue, pilotage des cessions carve out et des intégrations post-acquisitions ; 
  • digitalisation des opérations : traçabilité en temps réel via l’IoT (flux, transport, marchés parallèles, respect des températures…), prévisions de la demande, maîtrise des procédés de fabrication, développement de la maintenance prédictive, déploiement d’APS (Advanced Planification Scheduling)…
  • performance économique et maîtrise des coûts : (re)design to value, efficacité de la fonction achats / should-cost des packagings, compétitivité industrielle, réduction des stocks, réduction des SG&A (Sales, General & Administration, Frais généraux et administratifs), optimisation du cost to serve et des circuits logistiques, gouvernance et pilotage de la performance ; 
  • agilité : développement de nouveaux produits, synchronisation de la chaîne de planification et exécution : vendre >> réapprovisionner >> produire >> commander, réactivité et flexibilité industrielle (MTO/MTS, taille de campagne de production, répartition des stocks de sécurité et stabilisation du signal de demande) ; 
  • compliance : gestion du change control, choix du modèle de sérialisation et maîtrise du time to market, processus de libération, mise sous contrôle des master data ; 
  • collaboration : pilotage de la supply chain et déploiement d’APS (Advanced Planning & Scheduling), interaction avec les CDMO (Contract Development and Manufacturing Organisations) à travers le supplier developpment, la planification collaborative avec les façonniers, la maîtrise des risques des sources d’approvisionnement.

Sciences de la vie : études de cas

Planning hub location selection

pharmaceutical company

Planning hub location selection

Pfizer is one of the world’s leading innovative biopharmaceutical companies, developing over 100 different medicines and consumer healthcare products every year.

In order to drive excellence and reduce costs the demand planning functions across Europe were to be centralised into a regional hub. Senior stakeholders were unsure of the best location based on cost saving potential and availability of qualified people.

 

  • Assess and analyse the demand planning labour market in a number of key regions; Southern Europe, Eastern Europe, India and the Baltics
  • Research key socio-economic elements for each country, conduct analysis and make recommendations
  • Create a report on the recommendations including supporting evidence
  • Comprehensive report detailing the estimated cost saving and demand planning experience in each country
  • Recommendations for two options; low cost (circa 70% cost saving vs Western Europe benchmark) and a lower risk option
  • Planning hub location selected from the options provided

Global operating model development

global pharma

Global operating model development

Merck is a major global pharmaceutical company that discovers, develops, manufactures and markets a wide range of innovative pharmaceutical products. This includes vaccines, medications, and consumer and animal health products. It is headquartered in New Jersey, USA with worldwide marketing and manufacturing sites.

The company was in the early stages of implementing new planning systems and processes. However, there was no common understanding of what the end to end planning landscape would look like.

 

  • Collate the planning process designs into one global operating model (GOM) document
  • Document the supply chain design to support the change process
  • Designed a global operating model covering demand management, supply management and S&OP
  • All processes documented with linkages, responsibilities and metrics and incorporating cross-industry best practice
  • Business-wide understanding of the ‘to-be’ planning model and the changes to current ways of working

 

Logistics contracting

global pharma

Logistics contracting

GSK is a global healthcare company with three divisions: pharmaceuticals, vaccines and consumer healthcare. The company has commercial operations in more than 150 countries, a network of 86 manufacturing sites in 36 countries and large R&D centres in the UK, USA, Spain, Belgium and China.

The company had created a new venture in the consumer health area, and needed to consolidate in-market logistics contracts. New logistics contracts were required, in addition to rolling out standard contracts. The scope covered a number of markets across Europe.

 

  • Drive new transport and warehousing contracts with a wide variety of logistics contractors across Europe
  • Identify opportunities for cost reduction and efficiencies through benchmarking and analysis
  • Document and report the project to ensure alignment with other initiatives
  • New contracts negotiated and agreed based on a standard contract format
  • Fully benchmarked costs and performance
  • Cost savings and efficiencies of 3%-5%
  • Recommendations on which areas would benefit from a market RFP to drive further cost reduction

 

Order to cash process improvement

global biopharma

Order to cash process improvement

Bristol-Myers Squibb (BMS) is a global biopharma company focused on delivering innovative medicines to help patients fight serious diseases.

Following the shift of their business, financial, procurement, HR and IT services into a European above market capability centre, BMS was looking to standardise and optimise processes to improve operational efficiency and enhance the customer experience. The client needed our help to identify improvement opportunities in the end to end order to cash process.

 

  • Assess existing order to cash processes across 20+ EMEA markets
  • Benchmark processes against industry best practice to identify improvement opportunities
  • Evaluate and prioritise improvement opportunities to establish an implementation roadmap
  • Identified 37 opportunities to improve operational efficiency and increase customer satisfaction
  • Workstreams prioritised based on a number of factors (complexity, benefits, impact, resources, strategic alignment)
  • Stakeholder buy-in across all levels
  • A manageable programme of 20+ workstreams with a PMO to manage progress

 

 

Multi-regional network strategies

agrichemicals

Multi-regional network strategies

The largest of second-tier agrichemical businesses, Arysta operates in more than 100 countries worldwide with key markets in Brazil, North America and Europe. Arysta LifeScience manages a portfolio of more than 200 active ingredients with 4,000 employees worldwide.

The company wanted to review its North American and European networks to understand the opportunities for cost savings.

  • Model the ex-factory network flows, costs and options in Europe and North America
  • Analyse industry standard transport costs versus rates paid to identify what the cost should be
  • Model the optimum networks for Europe and North America to deliver to all key markets within eight hours
  • Create compelling business cases for each network

 

  • Identified that network opportunities were in managing the current cost structures more effectively
  • Identified 20% savings in the European transport operation and 50% in the US transport operation
  • Identified significant benefits in optimising the location of inventory and warehouses in US
  • Solution implemented by the company